MARKET

CGON

CGON

CG Oncology, Inc.
NASDAQ
72.07
+2.75
+3.97%
After Hours: 72.50 +0.43 +0.60% 19:54 05/12 EDT
OPEN
69.32
PREV CLOSE
69.32
HIGH
72.43
LOW
68.94
VOLUME
1.64M
TURNOVER
--
52 WEEK HIGH
73.56
52 WEEK LOW
23.32
MARKET CAP
6.36B
P/E (TTM)
-34.6058
1D
5D
1M
3M
1Y
5Y
1D
CG Oncology to present Phase 2 trial results for cretostimogene-gemcitabine combo in NMIBC
PUBT · 1d ago
CG Oncology Price Target Raised to $96.00/Share From $91.00 by JP Morgan
Dow Jones · 1d ago
CG Oncology Is Maintained at Overweight by JP Morgan
Dow Jones · 1d ago
JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $96
Benzinga · 1d ago
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
Benzinga · 1d ago
CG Oncology Price Target Raised to $81.00/Share From $79.00 by RBC Capital
Dow Jones · 1d ago
CG Oncology Is Maintained at Outperform by RBC Capital
Dow Jones · 1d ago
RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $81
Benzinga · 1d ago
More
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Webull offers CG Oncology Inc stock information, including NASDAQ: CGON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGON stock methods without spending real money on the virtual paper trading platform.